We are live on ! Find out more
FO

FT Options Portfolio holdings

AUM $66.4M Turnover 60.61%
1-Year Est. Return 18.48%
This Fund
S&P 500
This Quarter Est. Return
+24.92%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$126M
AUM Growth
+$9.7M
Cap. Flow
-$2.73M
Cap. Flow %
-2.16%
Top 10 Hldgs %
37.67%
Holding
493
New
153
Increased
113
Reduced
67
Closed
127
Avg Time Held Equity + Options
0.3 years
Top 10 Avg Time Held Equity + Options
0.3 years
Top 20 Avg Time Held Equity + Options
0.3 years
Avg Time Held Equity only
0.2 years
Top 10 Avg Time Held Equity only
0.3 years
Top 20 Avg Time Held Equity only
0.3 years

Top Buys

Rank Stock Value
1
PG icon
Procter & Gamble
PG
+$3.82M
2
BMY icon
Bristol-Myers Squibb
BMY
+$2.47M
3
IBB icon
iShares Biotechnology ETF
IBB
+$2M
4
ULTA icon
Ulta Beauty
ULTA
+$1.86M
5
MON
Monsanto Co
MON
+$1.82M

Top Sells

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$7.18M
2
BIIB icon
Biogen
BIIB
+$4.33M
3
CALM icon
Cal-Maine
CALM
+$3.64M
4
AAPL icon
Apple
AAPL
+$2.74M
5
ALR
Alere Inc
ALR
+$2.22M

Sector Composition

Rank Sector Weight
1 Healthcare 42.49%
2 Miscellaneous 37.27%
3 Consumer Staples 5.72%
4 Consumer Discretionary 5.23%
5 Technology 3.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
REGN icon
1
Regeneron Pharmaceuticals
REGN
$82.4B
$10.8M 8.6%
26,988
-4,366
-14% -$1.75M
2015 Q4
3 quarters
ABT icon
2
Abbott
ABT
$180B
$6.41M 5.08%
151,635
+24,383
+19% +$1.04M
2015 Q4
3 quarters
REGN icon
3
PUT
Regeneron Pharmaceuticals
REGN
$82.4B
$5.69M 4.51%
74,300
+27,300
+58% +$11M
2015 Q4
3 quarters
GWPH
4
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$5.16M 4.09%
131,100
+1,300
+1% +$124K
2015 Q4
3 quarters
PG icon
5
Procter & Gamble
PG
$368B
$4.04M 3.2%
45,000
+44,000
+4,400% +$3.82M
2016 Q2
1 quarter
BMY icon
6
Bristol-Myers Squibb
BMY
$125B
$3.96M 3.14%
73,537
+38,462
+110% +$2.47M
2016 Q2
1 quarter
AKBA icon
7
Akebia Therapeutics
AKBA
$193M
$3.31M 2.63%
366,118
-1,158
-0.3% -$9.8K
2015 Q4
3 quarters
SRPT icon
8
Sarepta Therapeutics
SRPT
$1.97B
$3.01M 2.39%
49,025
-11,883
-20% -$359K
2016 Q2
1 quarter
CLVS
9
DELISTED
Clovis Oncology, Inc.
CLVS
$2.56M 2.03%
71,091
+65,901
+1,270% +$1.41M
2015 Q4
3 quarters
OTIC
10
DELISTED
Otonomy, Inc.
OTIC
$2.53M 2.01%
139,085
-53,700
-28% -$878K
2016 Q1
2 quarters
IBB icon
11
iShares Biotechnology ETF
IBB
$10.9B
$2.03M 1.61%
+21,000
New +$2M
2016 Q3
0 quarters
ICPT
12
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$2.01M 1.6%
78,500
+58,300
+289% +$9.19M
2015 Q4
3 quarters
MON
13
DELISTED
Monsanto Co
MON
$1.77M 1.4%
+17,313
New +$1.82M
2016 Q3
0 quarters
ULTA icon
14
Ulta Beauty
ULTA
$25.8B
$1.75M 1.39%
+7,362
New +$1.86M
2016 Q3
0 quarters
HUM icon
15
Humana
HUM
$51.4B
$1.64M 1.3%
9,300
+1,450
+18% +$252K
2015 Q4
3 quarters
POT
16
DELISTED
Potash Corp Of Saskatchewan
POT
$1.55M 1.23%
95,080
-1,000
-1% -$16.5K
2015 Q4
3 quarters
ICPT
17
PUT
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.53M 1.21%
12,900
– –
2015 Q4
3 quarters
CASC
18
DELISTED
Cascadian Therapeutics, Inc.
CASC
$1.5M 1.19%
152,929
-33,348
-18% -$236K
2015 Q4
3 quarters
RCKT icon
19
Rocket Pharmaceuticals
RCKT
$258M
$1.49M 1.18%
39,216
+3,028
+8% +$95.2K
2015 Q4
3 quarters
TEVA icon
20
Teva Pharmaceutical Industries Limited
TEVA
$48.1B
$1.44M 1.14%
+31,300
New +$1.63M
2016 Q3
0 quarters
PBYI icon
21
Puma Biotechnology
PBYI
$547M
$1.43M 1.13%
+21,338
New +$1.08M
2016 Q3
0 quarters
RDUS icon
22
DELISTED
Radius Health, Inc.
RDUS
$1.39M 1.1%
+25,753
New +$1.31M
2016 Q3
0 quarters
EXEL icon
23
CALL
Exelixis
EXEL
$15.9B
$1.35M 1.07%
236,300
+45,600
+24% +$493K
2016 Q1
2 quarters
BMY icon
24
PUT
Bristol-Myers Squibb
BMY
$125B
$1.31M 1.04%
97,200
+47,200
+94% +$3.03M
2016 Q1
2 quarters
YHOO
25
DELISTED
Yahoo Inc
YHOO
$1.31M 1.04%
30,341
– –
2015 Q4
3 quarters
1
2 3 4 5

Similar funds

MC
Micawber Capital Seattle, Washington $62.9M AUM 20.32% 1-Year Est. Return
FIM
Friedberg Investment Management Houston, Texas $61.9M AUM 20.07% 1-Year Est. Return
TLIC
Thai Life Insurance Company Bangkok, Thailand $71M AUM 20.14% 1-Year Est. Return
MKCM
Mount Kellett Capital Management New York $61M AUM 12.22% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
MFM
Marianas Fund Management New York $58.1M AUM 10.84% 1-Year Est. Return
VE
Vega Energy New York $75.5M AUM 15.36% 1-Year Est. Return
GFWEV
G.F.W. Energy VIII Irving, Texas $76.3M AUM 11.41% 1-Year Est. Return

FT Options's Q3 2016 Portfolio in Review

As of Q3 2016, FT Options held 493 positions worth $126M, up 8.4% from $116M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

FT Options's Q3 2016 filing shows 153 new, 113 increased, 67 reduced and 127 closed positions. Its largest new stake was iShares Biotechnology ETF: 21,000 shares worth $2.03M. The largest sale was MEDIVATION, INC., an estimated $7.18M.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 41% a quarter earlier, followed by Miscellaneous and Consumer Staples.

  • FT Options's largest Q3 2016 buy was iShares Biotechnology ETF: 21,000 shares worth $2.03M.
  • FT Options added most to Procter & Gamble in Q3 2016, an estimated $3.82M increase.
  • FT Options's biggest Q3 2016 reduction was Apple, cutting an estimated $2.74M.
  • FT Options fully exited MEDIVATION, INC. in Q3 2016, selling an estimated $7.18M.
  • FT Options's ten largest holdings make up 38% of its $126M portfolio in Q3 2016.
  • FT Options opened 153 new positions and closed 127 in Q3 2016.
  • FT Options's portfolio value rose 8.4% quarter-over-quarter to $126M.

Based on FT Options's 13F filing for Q3 2016, filed 10 Nov 2016.